Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrated analysis of multimodal single-cell data
Hao, Y., Hao, S., Andersen-Nissen, E., Mauck, W. M., Zheng, S., Butler, A., Lee, M. J., Wilk, A. J., Darby, C., Zagar, M., et al. (2020) · doi:10.1101/2020.10.12.335331 · Cited by 15,508
Fast, sensitive and accurate integration of single-cell data with Harmony
Korsunsky, I., Millard, N., Fan, J., Slowikowski, K., Zhang, F., Wei, K., Baglaenko, Y., Brenner, M., Loh, P.-R., & Raychaudhuri, S. (2019) · Nature Methods · doi:10.1038/s41592-019-0619-0 · Cited by 10,488 · cited 1×
“To integrate all samples from the same project into a joint data structure, batch effects were mitigated using an integration algorithm that preserves biological diversity while removing artifacts (Harmony 55 ).”
MethodTisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735 · cited 1×
“Similar observations have been made with CAR-T cell products—for example, CD19-specific CAR-T cells 45 —and illustrate a distinguishing feature of cell-based therapies versus other classes of drugs.”
MethodUse of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Liu, E., Marin, D., Banerjee, P., Macapinlac, H. A., Thompson, P., Basar, R., Nassif Kerbauy, L., Overman, B., Thall, P., Kaplan, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910607 · Cited by 2,217 · cited 2×
“…blood and in vitro co-cultured CAR-NKTs showed similar changes in gene expression as well as distribution of cells in four of the seven expression clusters (2, 3, 4 and 6), exemplified by the acquisition of terminal effector differentiation and loss of the naive/memory program (Extended Data Fig.”
BackgroundA human memory T cell subset with stem cell–like properties
Gattinoni, L., Lugli, E., Ji, Y., Pos, Z., Paulos, C. M., Quigley, M. F., Almeida, J. R., Gostick, E., Yu, Z., Carpenito, C., et al. (2011) · Nature Medicine · doi:10.1038/nm.2446 · Cited by 1,974 · cited 1×
“As with our findings in NKTs, CD62L + central memory T cells have been shown to possess stem-cell-like properties, with the ability to self-renew while also giving rise to effector memory and effector T cells 46 .”
ResultAnti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
Yu, A. L., Gilman, A. L., Ozkaynak, M. F., London, W. B., Kreissman, S. G., Chen, H. X., Smith, M., Anderson, B., Villablanca, J. G., Matthay, K. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911123 · Cited by 1,835 · cited 2×
“Regarding other AEs, patients on our study and most other early-phase GD2-CAR-T cell studies did not experience neuropathic pain 11,13,14 , which commonly occurs with GD2-specific antibodies, including dinutuxi-mab, and can require intravenous opioid administration 32 .”
BackgroundLong, A. H., Haso, W. M., Shern, J. F., Wanhainen, K. M., Murgai, M., Ingaramo, M., Smith, J. P., Walker, A. J., Kohler, M. E., Venkateshwara, V. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3838 · Cited by 1,815
The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells
Mestermann, K., Giavridis, T., Weber, J., Rydzek, J., Frenz, S., Nerreter, T., Mades, A., Sadelain, M., Einsele, H., & Hudecek, M. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau5907 · Cited by 531 · cited 3×
“…blood and in vitro co-cultured CAR-NKTs showed similar changes in gene expression as well as distribution of cells in four of the seven expression clusters (2, 3, 4 and 6), exemplified by the acquisition of terminal effector differentiation and loss of the naive/memory program (Extended Data Fig.”
BackgroundMethodGraef, P., Buchholz, V. R., Stemberger, C., Flossdorf, M., Henkel, L., Schiemann, M., Drexler, I., Höfer, T., Riddell, S. R., & Busch, D. H. (2014) · Immunity · doi:10.1016/j.immuni.2014.05.018 · Cited by 311
Giles, J. R., Ngiow, S. F., Manne, S., Baxter, A. E., Khan, O., Wang, P., Staupe, R., Abdel-Hakeem, M. S., Huang, H., Mathew, D., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01338-4 · Cited by 264
Self-citation
Cited by
Reinstein, Z. Z., Zhang, Y., Ospina, O. E., Nichols, M. D., Chu, V. A., Pulido, A. D. M., Prieto, K., Nguyen, J. V., Yin, R., Moran Segura, C., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0798 · Cited by 33
Metadata
- Authors
- Heczey, A., Xu, X., Courtney, A. N., Tian, G., Barragan, G. A., Guo, L., Amador, C. M., Ghatwai, N., Rathi, P., Wood, M. S., Li, Y., Zhang, C., Demberg, T., Di Pierro, E. J., Sher, A. C., Zhang, H., Mehta, B., Thakkar, S. G., Grilley, B., Wang, T., Weiss, B. D., Montalbano, A., Subramaniam, M., Xu, C., Sachar, C., Wells, D. K., Dotti, G., & Metelitsa, L. S.
- Venue
- Nature Medicine
- Published
- 2023-05-15
- Volume
- 29
- Issue
- 6
- Pages
- 1379-1388
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W4376610678
- Cited by
- 204
- References
- 12
- FWCI
- 21.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results. https://app.cochat.ai/papers/10.1038/s41591-023-02363-y
- The paper
- Heczey, A., Xu, X., Courtney, A. N., Tian, G., Barragan, G. A., Guo, L., Amador, C. M., Ghatwai, N., Rathi, P., Wood, M. S., Li, Y., Zhang, C., Demberg, T., Di Pierro, E. J., Sher, A. C., Zhang, H., Mehta, B., Thakkar, S. G., Grilley, B., . . . Metelitsa, L. S. (2023). Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results. Nature Medicine. https://doi.org/10.1038/s41591-023-02363-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.